Description of Collaborative Activity: |
The final product of an NIH Consensus Conference is a written statement on a controversial medical topic prepared by an independent panel of health professionals free from conflicts of interest on the basis of the results of a systematic literature review, presentations by experts in the field, and public comments and questions. Inhaled nitric oxide therapy was approved by the U.S. Food and Drug Administration in 2000 to treat term and near-term infants with respiratory failure. Since its approval, researchers have examined expanding the use of inhaled nitric oxide therapy to treat premature babies born at less than 34 weeks gestation. Studies to evaluate its safety and efficacy for these infants have had mixed results in terms of key outcomes. The goal of this conference was to clarify the role of inhaled nitric oxide in this population. The meeting was held on October 27-29, 2010. |
